Overview

Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer

Status:
Completed

Trial end date:
2021-04-09

Target enrollment:

Participant gender:

Summary

This Phase II research project will test the efficacy, safety, and tolerability of an experimental drug combination: either nivolumab and BBI608 or nivolumab and BNC105 in patients with metastatic colorectal cancer who have previously failed standard of care treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Australasian Gastro-Intestinal Trials Group

Treatments:

Antibodies, Monoclonal
Nivolumab